Business
Parsortix Colorectal Cancer Validation
Parsortix Colorectal Cancer Validation.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 7804I Angle PLC 08 July 2013 \n \n\n\n\n\n\nFor immediate release \n \n\n\n8 July 2013\n\n\n\n\n \nANGLE plc \n(\"ANGLE\" or \"the Company\")\n \nPARSORTIX COLORECTAL CANCER PATIENT BLOOD VALIDATION \n \n \nANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce successful results from third party testing of its Parsortix non-invasive cancer diagnostic product on colorectal cancer patient blood. \n \nThe Parsortix system comprising the PR1 machine and the GEN3 cassette was tested on cancer patient blood by the University of Surrey Oncology Group (Surrey) and has been found to be performing well.\n \nSurrey researchers first undertook a wide range of testing on controlled spiked samples (cultured cancer cells added to healthy volunteer blood) with a variety of different types of cancer. This testing enabled them to compare capture and harvesting of cells against known numbers of spiked cells and was completed successfully as a pre-cursor to testing the blood of cancer patients. Surrey also developed and refined formal cell identification techniques with the Parsortix system.\n \nFollowing a number of successful separations of the blood of patients with a variety of different cancers, Surrey has completed a structured analysis of colorectal cancer patient blood undertaken by a hepatopancreobiliary surgeon from the Royal Surrey County Hospital.\n \nCells from 2ml samples of whole blood from 20 colorectal cancer patients were separated and harvested using the Parsortix system. The harvested cells were investigated by Surrey to identify and count the CTCs (circulating tumour cells) in the patients' blood.\n \nOf the 20 patients tested, 75% were found positive for CTCs. This is an impressive result as it is more than double the level recorded in the published literature*, which suggests that a positive CTC count (defined as 2 or more CTCs in 7.5ml of blood) will be found in less than half this number of patients. The effectiveness of the Parsortix cell harvest is even more pronounced as only 2ml of blood was used, less than one third of the sample volume used in the published studies. \n \nSurrey has subsequently demonstrated that, through the use of the simple and established Ficoll gradi...